GSE78199 tamoxifen 2 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE78199_tamoxifen_2_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE78199_tamoxifen_2_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE78199_tamoxifen_2_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE78199_tamoxifen_2_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

Pvt1 oncogene

Gene

small nucleolar RNA host gene 15

Gene

small nucleolar RNA host gene 17

Gene

VPS9D1 antisense RNA 1

Gene

small nucleolar RNA host gene 26

Gene

family with sequence similarity 86, member A pseudogene

Gene

LDL receptor related protein 5 like (pseudogene)

Gene

cancer/testis associated 62

Gene

SLC25A24 pseudogene 1

Gene

long intergenic non-protein coding RNA 2884


  • Gene

    small nucleolar RNA host gene 15


  • Gene

    small nucleolar RNA host gene 17


  • Gene

    VPS9D1 antisense RNA 1


  • Gene

    small nucleolar RNA host gene 26


  • Gene

    family with sequence similarity 86, member A pseudogene


  • Gene

    LDL receptor related protein 5 like (pseudogene)


  • Gene

    cancer/testis associated 62


  • Gene

    SLC25A24 pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 2884

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.